Study of Cabozantinib Plus TAS102 in mCRC as Salvage Therapy
Status:
Recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
This is a phase I clinical trial assessing the safety and recommended phase II dose of
cabozantinib in combination with trifluridine/tipiracil (TAS102) in patients with metastatic
colorectal carcinoma (mCRC).